It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
This test can be run on commonly available qPCR cyclers, thereby, bypassing the need to perform expensive and time-consuming Next-Generation Sequencing
Over 70 per cent of the world’s population have no access to MRI scanners and the situation is not that encouraging in India where there are only 0.4 MRI scanners per thousand people
Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
The lab will offer over 4,000 clinical tests and profiles and can conduct over 20,000 sample tests per month.
Subscribe To Our Newsletter & Stay Updated
